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Abstract 
Objectives Patients with rheumatoid arthritis (RA) have an excess risk of cardiovascular disease 
(CVD). We aimed to assess the impact of CVD risk factors, including potential sex differences, and 
RA-specific variables on CVD outcome in a large, international cohort of patients with RA. 
 
Methods In 13 rheumatology centres, data on CVD risk factors and RA characteristics were collected 
at baseline. CVD outcomes (myocardial infarction, angina, revascularisation, stroke, peripheral 
vascular disease and CVD death) were collected using standardised definitions. 
 
Results 5638 patients with RA and no prior CVD were included (mean age: 55.3 (SD: 14.0) years, 76% 
women). During mean follow-up of 5.8 (SD: 4.4) years, 148 men and 241 women developed a CVD 
event (10-year cumulative incidence 20.9% and 11.1%, respectively). Men had a higher burden of 
CVD risk factors, including increased blood pressure, higher total cholesterol and smoking 
prevalence than women (all p<0.001). Among the traditional CVD risk factors, smoking and 
hypertension had the highest population attributable risk (PAR) overall and among both sexes, 
followed by total cholesterol. The PAR for Disease Activity Score and for seropositivity were 
comparable in magnitude to the PAR for lipids. A total of 70% of CVD events were attributable to all 
CVD risk factors and RA characteristics combined (separately 49% CVD risk factors and 30% RA 
characteristics). 
 
Conclusions In a large, international cohort of patients with RA, 30% of CVD events were attributable 
to RA characteristics. This finding indicates that RA characteristics play an important role in efforts to 
reduce CVD risk among patients with RA. 
Introduction 
Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD),1 
which may be attributable to a combination of traditional CVD risk factors and RA-specific 
characteristics.2 3 In a recent meta-analysis, hypertension, diabetes mellitus, hypercholesterolaemia 
and obesity were shown to increase the risk of CVD in patients with RA.4 
 
Successful prevention of CVD requires identification of persons at high risk. However, for patients 
with RA, established CVD risk calculators have been shown to provide inaccurate estimates.5 6 This 
imprecision may be due to several factors. Despite a high atherosclerotic burden, patients with RA 
have more silent myocardial infarctions (MI) compared with non-RA persons.7 This asymptomatic 
atherosclerosis in the carotid and coronary arteries may not be accounted for during CVD risk 
evaluation.8–10 
 
Another factor that may explain the incorrect estimation of CVD is the female preponderance. In the 
general population, it is well documented that women manifest CVD at older ages than men.11 
Possible differences between the sexes in risk factors associated with CVD have been explored in 
large general population cohorts.12–14 It is unknown whether the impact of traditional risk factors 
on CVD differs between the sexes in patients with RA. 
 
RA is an inflammatory joint disease and the increased risk of CVD is likely also related to disease-
specific factors, such as inflammation and disease activity. Inflammation also influences traditional 
CVD risk factors, such as lipoproteins.15 Patients with RA are known to have lower lipoprotein levels 
than non-RA persons,16–18 despite their increased CVD risk, because lipid levels decrease with 
increasing inflammation.16 17 19 20 This lipid paradox complicates the CVD risk evaluation of 
patients with RA.21 Therefore, it is recommended to assess the lipid profile when the disease is not 
active. Thus, the importance of each CVD risk factor on CVD outcomes in patients with RA may differ 
from that in the general population. 
 
The objectives of this study were to assess the impact of CVD risk factors and RA characteristics, 
including potential sex differences, on CVD outcomes in a large, international cohort of patients with 
RA. 
 
Patients and methods 
Study populations 
Thirteen cohorts of patients with RA originating from 10 different countries (UK, Norway, The 
Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico) were combined. 
Patients in each cohort were included based on physician diagnosis of RA and/or fulfilment of 1987 
or 2010 American College of Rheumatology criteria for RA. Cohorts followed patients prospectively 
through study visits at regular intervals or retrospectively through medical record review. Data were 
collected using standardised definitions, but patient management strategies were not standardised. 
Details regarding these cohorts are located on the consortium website (http://www.atacc-ra.com) 
and in our previous publication.22 The study complied with the Declaration of Helsinki, was 
approved by ethical boards/committees at each centre, and informed consent was obtained from 
the subjects where required. Data were anonymised and aggregated for analyses. 
 
Variable definitions 
The primary outcomes were fatal/non-fatal CVD events including acute coronary syndrome (ST-
elevation and non-ST elevation MI and unstable angina pectoris), chronic ischaemic heart disease 
(stable angina pectoris), coronary revascularisation (eg, percutaneous coronary intervention and 
coronary artery bypass grafting), CVD death, cerebrovascular events (ischaemic cerebrovascular 
accident and transient ischaemic attack) and peripheral vascular events (with and without 
revascularisation procedures, peripheral artery disease). Not included were cases of confirmed 
cerebral haemorrhage, non-coronary cardiac death, non-ischaemic CVD, heart failure and aortic 
aneurysm. 
 
Traditional CVD risk factors collected at baseline were age, sex, smoking status (current, former, 
never), systolic and diastolic blood pressure, lipid levels (total cholesterol (TC), high density 
lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c), triglycerides), body mass 
index (BMI), family history of CVD, diabetes mellitus and hypertension. Data on use of lipid-lowering 
medications and antihypertensives were also collected. 
 
RA-specific factors were collected at baseline including rheumatoid factor (RF) positivity, 
anticitrullinated protein antibodies (ACPA) positivity, erythrocyte sedimentation rate (ESR), C 
reactive protein (CRP) and Disease Activity Score including 28 joints (DAS28) using ESR. RF and ACPA 
were considered positive based on the tests performed at each centre. ACPA testing was unavailable 
in some patients. CRP was unavailable in one cohort, and DAS28 was unavailable in another cohort. 
Data on use of non-steroidal anti-inflammatory drugs (NSAIDs), Cox-2 inhibitors, glucocorticoids and 
RA therapies were also collected. 
 
Statistical methods 
Descriptive statistics (means, percentages and so on) were used to summarise characteristics at 
baseline by sex with comparisons performed using χ2 and rank-sum tests. Multiple imputation 
methods were used to impute missing values for CVD risk factors using 10 repetitions. Log-
transformations were used when imputing lipid levels to avoid bias when computing lipid ratios from 
imputed data.23 
 
The cumulative incidence of CVD by sex according to time since baseline and age was estimated 
using Kaplan-Meier methods. Adjusted curves were obtained using inverse probability weighting.24 
The influence of CVD risk factors and RA characteristics on development of CVD was estimated 
overall and separately by sex using multivariable Cox models. All models were stratified according to 
high and low CVD risk centres to account for underlying differences in CVD event rates and to avoid 
issues with instability of estimates for small centres. Univariable models adjusted for age and 
multivariable models containing all CVD risk factors and all CVD risk factor plus RA characteristics 
were examined. As sex differences were not substantially different for adjusted univariable models 
compared with multivariable models, only the multivariable model results were reported. Estimates 
for triglycerides were obtained by removing HDL-c and adding triglycerides to the overall 
multivariable model. 
 
Population attributable risk (PAR) is the proportion of disease in a population that could be 
prevented by elimination of an exposure or risk factor. PAR is commonly calculated as PAR = (P(D) – 
P(D|Ē))/P(D), where P(D) is the probability of disease (ie, CVD), and P(D|Ē) is the conditional 
probability of disease among individuals without the risk factor.25 PAR is a function of time, since it 
depends on the probability of disease and the prevalence of the risk factor, which changes over 
time. Thus, the cumulative incidence of CVD was used to estimate the probability of CVD over time, 
and these estimates were obtained from Cox models to allow for adjustment for multiple risk 
factors. The conditional probability of CVD over time for those without a risk factor was estimated 
from the same Cox models, but with a target cohort that matched the observed cohort except that it 
lacked the risk factor of interest. For continuous risk factors, such as lipid levels, target values 
representing desirable levels were chosen. An overall PAR considering the impact of a collection of 
risk factors was also obtained by utilising target cohorts modifying several risk factors 
simultaneously. The sum of PAR for single risk factors may not equal the PAR for a combination of 
several risk factors due to overlapping exposures and non-additive effects.26 Reported values of PAR 
correspond to 10 years after baseline, as 10 years is a commonly used time horizon for CVD risk 
assessment. p Values <0.05 were considered to be statistically significant. Analyses were performed 
using SAS V.9.4 and R V.3.2.0 (R Foundation for Statistical Computing, Vienna, Austria). 
 
Results 
Risk factors 
Baseline characteristics of the 5638 included patients with RA without prior CVD are presented in 
table 1. The mean age (±SD) in the total population was 55.3 (±14.0 years). There was a clear female 
preponderance (75.9% overall) with even higher female/male ratios among the two Hispanic 
cohorts. Statistically significant differences between the sexes were observed in the majority of the 
baseline characteristics. Male patients were older and had a higher burden of traditional CVD risk 
factors, including higher blood pressure/more hypertension and were more often smokers (p<0.001 
for all). Higher levels of CRP (p<0.001) were also seen in men compared with women. Women had 
slightly higher TC, HDL-c and ESR levels and were more frequent users of synthetic and biological 
disease-modifying antirheumatic drugs (DMARDs) (p<0.001 and 0.005, respectively). 
 
Table 1 
Descriptive baseline characteristics of 5638 patients with RA without prior CVD 
 
Characteristics 
Available  (
n) 
Overall (n=563
8) 
Female (n=42
78) 
Male (n=136
0) 
p 
Value 
 Length of 
follow-up, 
years 
5638 5.8 (4.4) 5.8 (4.4) 6.0 (4.6) – 
 Age, years 5638 55.3 (14.0) 54.7 (14.4) 57.2 (12.7) <0.00
1 
 White race 3945 3699 (94%) 2924 (93.4%) 775 (95.2%) 0.056 
Characteristics 
Available  (
n) 
Overall (n=563
8) 
Female (n=42
78) 
Male (n=136
0) 
p 
Value 
RA 
characteristics 
     
 Calendar 
year of RA 
diagnosis 
5628 1998.4 (9.9) 1998.1 (10.1) 1999.2 (9.1) 0.007 
 RA disease 
duration, years 
5628 6.4 (9.2) 6.9 (9.5) 4.9 (8.0) <0.00
1 
 RF and/or 
ACPA positive 
5485 3949 (72%) 2982 (71.8%) 967 (72.7%) 0.540 
 ESR, 
mm/hour 
4737 24.8 (21.4) 25.1 (20.9) 23.8 (22.8) <0.00
1 
 C reactive 
protein, mg/L 
4528 15.4 (27.1) 13.7 (24.8) 21.1 (33.0) <0.00
1 
 DAS28 4448 4.0 (1.7) 4.0 (1.7) 3.9 (1.7) 0.466 
Traditional 
CVD risk 
factors 
     
 Systolic 
blood pressure, 
mm Hg 
5345 136.0 (21.9) 134.3 (22.0) 141.3 (20.7) <0.00
1 
 Diastolic 
blood pressure, 
mm Hg 
5343 79.6 (11.1) 78.5 (11.0) 83.0 (10.7) <0.00
1 
 Total 
cholesterol, 
mmol/L 
4457 5.2 (1.1) 5.2 (1.1) 5.1 (1.1) <0.00
1 
 Low density 
lipoprotein, 
mmol/L 
4364 3.1 (1.0) 3.1 (1.0) 3.1 (1.0) 0.077 
 High density 
lipoprotein, 
mmol/L 
4403 1.5 (0.4) 1.5 (0.5) 1.3 (0.3) <0.00
1 
 Triglycerides, 
mmol/L 
4240 1.4 (0.8) 1.4 (0.7) 1.5 (1.0) 0.001 
Characteristics 
Available  (
n) 
Overall (n=563
8) 
Female (n=42
78) 
Male (n=136
0) 
p 
Value 
 Current 
smoker 
5368 1148 (21%) 788 (19.3%) 360 (28.1%) 0.001 
 Ever smoker 5120 2688 (52%) 1838 (47.1%) 850 (69.7%) <0.00
1 
 Body mass 
index, kg/m2 
5160 27.0 (5.4) 26.9 (5.7) 27.2 (4.4) <0.00
1 
 Hypertension 5618 2344 (42%) 1726 (40.5%) 618 (45.7%) 0.001 
 Diabetes 
mellitus 
5637 395 (7%) 290 (6.8%) 105 (7.7%) 0.237 
 Family 
history of CVD 
3677 876 (24%) 658 (23.8%) 218 (23.9%) 0.931 
Medication 
     
 
Antihypertensiv
es 
5608 1314 (23%) 1008 (23.7%) 306 (22.6%) 0.437 
 Lipid-
lowering 
therapy 
5604 510 (9%) 383 (9.0%) 127 (9.4%) 0.395 
 Synthetic 
DMARD 
5593 2610 (47%) 2085 (49.1%) 525 (38.9%) <0.00
1 
 Biological 
DMARD 
5592 891 (16%) 762 (18.0%) 129 (9.6%) <0.00
1 
 
Corticosteroid 
5590 1527 (27%) 1177 (27.7%) 350 (26.0%) 0.201 
 
Corticosteroid 
dosage, 
mg/day 
869 5.8 (4.4) 5.6 (4.2) 6.4 (5.2) 0.066 
 Values in table are mean (SD) or n (%). 
 ACPA, anticitrullinated protein antibody; CVD, cardiovascular disease; DAS28, Disease 
Activity Score including 28 joints; DMARD, disease-modifying antirheumatic drug; 
ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor. 
 
Outcomes 
During a mean (±SD) follow-up of 5.8 (±4.4) years, 389 patients (148 men and 241 women) 
developed CVD events (including 166 patients with MI, 88 with stable or unstable angina, 62 with 
revascularisation, 35 with cardiovascular deaths, 147 with cerebrovascular events and 46 with 
peripheral vascular events). The unadjusted cumulative incidence of CVD at 10 years after baseline 
was 20.9% (95% CI  17.3% to 24.4%) among men and 11.1% (95% CI 9.6% to 12.7%) among women. 
Adjustment for CVD risk factors had minimal impact on 10-year CVD risk estimates (19.2% among 
men and 11.4% among women). The cumulative incidence of CVD was higher in men than in women 
in all ages above 40 years (figure 1). 
 
Figure 1 
Figure 1 
Cumulative incidence of cardiovascular disease (CVD) among men (solid line) and women (dashed 
line) with rheumatoid arthritis according to age. 
 
Relative risk 
The age-adjusted relative risk of CVD was higher among men than women (HR: 1.74; 95% CI 1.41 to 
2.12). Additional adjustment for CVD risk factors reduced the sex effect slightly (HR: 1.49; 95% CI 
1.19 to 1.85; table 2). Age was significantly associated with CVD overall and in both sexes, and the 
age effect was not impacted by adjusting for other CVD risk factors. TC, LDL-c and triglycerides were 
all significantly associated with CVD following age adjustment, but no longer reached statistical 
significance following adjustment for other CVD risk factors. Among men the only lipid measure that 
was significantly associated with CVD was triglycerides, which remained statistically significant 
following adjustment for all CVD risk factors. Smoking and hypertension were strong predictors of 
CVD overall and among both sexes, even after adjustment for all other CVD risk factors. Diabetes 
mellitus was significantly associated with CVD among women, but did not reach statistical 
significance among men. BMI was not significantly associated with CVD. Regarding RA 
characteristics, DAS28 and RF/ACPA positivity were significantly associated with CVD with age 
adjustment, but were no longer significant after adjustment for all CVD risk factors. There was no 
evidence of differential effects between sexes regarding the association between CVD risk factors 
and CVD outcomes (interaction p>0.1 for all) or between RA characteristics and CVD outcomes 
(interaction p>0.6 for all). 
 
Table 2 
Adjusted HRs for cardiovascular disease for both sexes 
Table 2 
Adjusted HRs for cardiovascular disease for both sexes 
Risk factor 
Age-adjusted and 
sex-adjusted 
HR (95% CI) Multivariable-adjusted* HR (95% CI) 
p Value for 
sex 
difference 
Cardiovascular 
disease Overall Overall Women Men 
Male sex (vs 
female) 
1.74 (1.41 to 2.13) 1.49 
(1.19 to 
1.85) 
– – – 
Age, years† 1.70 (1.57 to 1.85) 1.66 
(1.52 to 
1.81) 
1.74 
(1.56 to 
1.94) 
1.54 
(1.33 to 
1.79) 
0.19 
Total 
cholesterol, 
mmol/L 
1.10 (1.02 to 1.20) 1.15 
(0.93 to 
1.43) 
1.06 
(0.80 to 
1.40) 
1.27 
(0.90 to 
1.77) 
0.94 
LDL-c, mmol/L 1.15 (1.04 to 1.27) 1.00 
(0.79 to 
1.27) 
1.11 
(0.81 to 
1.52) 
0.89 
(0.62 to 
1.29) 
0.29 
HDL-c, mmol/L 0.73 (0.56 to 0.95) 0.67 
(0.48 to 
0.93) 
0.76 
(0.51 to 
1.15) 
0.51 
(0.28 to 
0.94) 
0.82 
Triglycerides, 
mmol/L‡ 
1.17 (1.06 to 1.30) 1.13 
(0.99 to 
1.29) 
1.08 
(0.89 to 
1.31) 
1.24 
(1.01 to 
1.51) 
0.79 
Current smoker 2.05 (1.58 to 2.67) 1.98 
(1.52 to 
2.58) 
1.79 
(1.28 to 
2.50) 
2.50 
(1.56 to 
4.03) 
0.20 
Risk factor 
Age-adjusted and 
sex-adjusted 
HR (95% CI) Multivariable-adjusted* HR (95% CI) 
p Value for 
sex 
difference 
Cardiovascular 
disease Overall Overall Women Men 
Former smoker 1.46 (1.14 to 1.86) 1.43 
(1.12 to 
1.83) 
1.36 
(1.01 to 
1.82) 
1.75 
(1.10 to 
2.79) 
0.39 
Hypertension 1.62 (1.31 to 2.00) 1.59 
(1.28 to 
1.96) 
1.40 
(1.07 to 
1.84) 
1.95 
(1.38 to 
2.75) 
0.30 
Diabetes 
mellitus 
1.49 (1.08 to 2.06) 1.39 
(0.99 to 
1.95) 
1.62 
(1.06 to 
2.50) 
1.13 
(0.66 to 
1.96) 
0.42 
Body mass 
index, kg/m2 
1.01 (0.99 to 1.03) 1.00 
(0.98 to 
1.02) 
1.00 
(0.97 to 
1.02) 
1.00 
(0.96 to 
1.04) 
0.79 
Rheumatoid 
arthritis 
     
 DAS28 ≥3.2 1.40 (1.03 to 1.90) 1.24 
(0.91 to 
1.70) 
1.32 
(0.88 to 
1.98) 
1.12 
(0.68 to 
1.84) 
0.80 
 RF/ACPA 
positive 
1.30 (1.02 to 1.65) 1.23 
(0.96 to 
1.56) 
1.26 
(0.92 to 
1.70) 
1.18 
(0.79 to 
1.76) 
0.99 
 ESR, 
mm/hour† 
1.02 (0.98 to 1.07) 1.01 
(0.97 to 
1.06) 
1.03 
(0.96 to 
1.09) 
1.01 
(0.94 to 
1.08) 
0.68 
 CRP, mg/L† 1.02 (0.99 to 1.04) 1.01 
(0.98 to 
1.04) 
1.01 
(0.96 to 
1.05) 
1.02 
(0.97 to 
1.06) 
0.82 
 *All cardiovascular risk factors were included in one multivariable model for each sex, 
except triglycerides. Each rheumatoid arthritis variable was subsequently added to the 
overall and sex-specific multivariable models including all the cardiovascular disease 
risk factors. 
 †Per 10 unit increase. 
 ‡Estimates for triglycerides were obtained by removing HDL-c and adding triglycerides 
to the overall multivariable model. 
 ACPA, anticitrullinated protein antibodies; CRP, C reactive protein; DAS28, Disease 
Activity Score including 28 joints; ESR, erythrocyte sedimentation rate; HDL-c, high 
density lipoprotein cholesterol; LDL-c, Low density lipoprotein cholesterol; RF, 
rheumatoid factor. 
 
Population attributable risk 
PAR estimates the fraction of CVD events that could be prevented by a potential target intervention. 
Hence, PAR is a function of risk factor prevalence, effect size and a chosen target. Smoking and 
hypertension had the highest PAR values overall and among both sexes (figure 2 and table 3). PAR 
for smoking and for hypertension were nearly twice as high among men than women (37.2% vs 
18.1% and 26.1% vs 14.7%, respectively), but these differences did not reach statistical significance 
(p=0.12 and p=0.24, respectively). PAR for TC was 11.5% overall, with an insignificantly higher PAR 
among men than women (p=0.56). PAR for the remaining CVD risk factors was <10% overall and for 
both sexes. For the RA characteristics, DAS28 and RF/ACPA positivity had similar PAR to TC (12.6% 
and 12.2%, respectively). PAR for decreasing DAS28 when decreasing it to 3.2, if >3.2 at baseline was 
16.9% among women compared with 6.2% among men (p=0.46). PAR for RF/ACPA was also higher 
among women than men (13.7% vs 9.4%), but not significantly (p=0.74). PAR for ESR and for CRP 
were <5% overall and for both sexes. 
 
In aggregate, all the CVD risk factors in table 3 combined explained 49.0% of the CVD risk in patients 
with RA. The RA characteristics explained 30.3% of the CVD risk, and the CVD risk factors and RA 
characteristics combined explained 69.6% of the CVD risk. PAR for all the CVD risk factors combined 
was higher among men (61.1%) than among women (42.8%), but this difference was not statistically 
significant (p=0.29). In contrast, PAR for all RA characteristics combined was higher among women 
(39.9%) than among men (18.0%), but not significantly (p=0.39). Furthermore, when both CVD risk 
factors and RA characteristics were combined, the PAR for men and women was similar (72.7% vs 
69.3%, respectively, p=0.82). Additional adjustment for use of antihypertensives, lipid-lowering 
medications, NSAIDs, Cox-2 inhibitors, glucocorticoids and family history of CVD had little impact 
(2.0% increase in PAR). 
 
Figure 2 
 Figure 2 
Population attributable risk for cardiovascular risk factors and RA characteristics overall (panel A), 
among women (panel B) and among men (panel C). ACPA, anticitrullinated protein antibodies; CRP, 
C reactive protein; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid 
factor. 
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Table 3 
Population attributable risk for 10-year cardiovascular disease risk by sex 
 
Risk factor Target values 
Multivariable-adjusted*  
Population attributable risk, 
% 
p Value for 
sex difference 
Cardiovascular 
disease 
 
Overall Women Men 
Total cholesterol, 
mmol/L 
Decreased to 
4.5 mmol/L 
11.5 5.4 15.7 0.56 
LDL-c, mmol/L Decreased to 
2.5 mmol/L 
0.2 8.1 −9.1 0.41 
HDL-c, mmol/L Increased to 1.2 mmol/L 
for women, 1.0 mmol/L 
for men 
1.1 0.8 1.7 0.43 
Triglycerides, 
mmol/L† 
Decreased to 
1.7 mmol/L 
2.6 1.5 4.8 0.29 
Current/former 
smoker 
Never smoked 23.7 18.1 37.2 0.12 
Hypertension Absence 19.6 14.7 26.1 0.24 
Diabetes mellitus Absence 2.7 4.0 1.0 0.39 
Body mass index, 
kg/m2 
Decreased to 25 kg/m2 −0.2 −0.7 1.2 0.81 
Rheumatoid 
arthritis 
     
 DAS28 ≥3.2 Decreased to <3.2 12.6 16.9 6.2 0.46 
 RF/ACPA 
positive 
Negative 12.2 13.7 9.4 0.74 
 ESR, mm/hour Decreased to 
20 mm/hour 
1.2 2.7 0.5 0.76 
 CRP, mg/L Decreased to 5 mg/L 1.5 0.7 2.5 0.77 
All CVD risk 
factors 
 
49.0 42.8 61.1 0.29 
All RA 
characteristics 
 
30.3 39.9 18.0 0.39 
Risk factor Target values 
Multivariable-adjusted*  
Population attributable risk, 
% 
p Value for 
sex difference 
Cardiovascular 
disease 
 
Overall Women Men 
All CVD and all RA characteristics 69.6 72.7 69.3 0.87 
 *All CVD risk factors (including age) were included in one multivariable model for each 
sex, except triglycerides. Each RA variable was subsequently added to each sex-
specific multivariable model including all the CVD risk factors. 
 †Estimates for triglycerides were obtained by removing HDL-c and adding triglycerides 
to the overall multivariable model. 
 ACPA, anticitrullinated protein antibodies; CRP, C reactive protein; 
CVD, cardiovascular disease; DAS28, Disease Activity Score including 28 joints; ESR, 
erythrocyte sedimentation rate; HDL-c, high density lipoprotein cholesterol; LDL-c, low 
density lipoprotein cholesterol; RA, rheumatoid arthritis; RF, rheumatoid factor. 
 
Discussion 
Our study illuminated that both traditional and RA-specific factors had significantly different 
prevalence among women and men with RA. There was a sex difference in CVD event rates in 
patients with RA for all ages above 40 years, and this was independent of traditional CVD risk factors 
and markers of RA disease activity. Despite sex differences in the prevalence of many risk factors, 
the relative risks for CVD for the risk factors did not differ between the sexes, and this resulted in no 
significant differences in the PAR between the sexes. Altogether, the CVD risk factors and RA 
characteristics explained 70% of the PAR for CVD outcomes, leaving 30% unaccounted for. 
 
Our findings among patients with RA of no differential effects of CVD risk factors between the sexes 
differed from reports in the general population. The INTERHEART study found that smoking had a 
higher impact on CVD among men than women, and hypertension and diabetes mellitus had a 
higher impact among women than men.13 Schnohr et al 27 also found a higher impact of diabetes 
mellitus on CVD risk among women compared with men, but no differential sex effect for 
hypertension. In contrast, they found a higher impact of smoking on CVD among women compared 
with men.27 While the relative risk of diabetes mellitus in our study was also higher for women than 
men, the effect of smoking appeared to be greater in men than women, but neither difference 
reached statistical significance. The female predominance of RA may have limited statistical power 
for these comparisons despite the large sample size in this study. 
 
Our findings that smoking and hypertension had the highest PAR were consistent with the findings 
from the INTERHEART study and Schnohr et al.27 28 Our PAR for smoking (18.1% for women and 
37.2% for men) was similar to the INTERHEART study (15.8% for women and 44.0% for men), which 
differed from Schnohr et al (37% among women and 22% among men). PAR for hypertension also 
differed between the INTERHEART study (35.8% among women and 19.5% among men) and Schnohr 
et al (14% among women and 18% among men), but in this case our PAR (14.7% among women and 
26.1% among men) was closer to those of Schnohr et al. Likewise our PAR for diabetes mellitus (4.0% 
among women and 1.0% among men) agreed more closely with Schnohr et al (3% for both sexes) 
than with INTERHEART (19.1% among women and 10.1% among men). The reasons for these 
disparate PARs between studies in the general population are unknown. However, there could be 
differences in smoking exposures or in hypertension control between these study populations. 
 
Concordant with our findings, neither of the general population studies noted differential effects of 
lipids on CVD between sexes.13 27 The relation of LDL-c and CVD events appeared to be U-shaped 
for both RA and non-RA persons.29 Low levels of LDL-c have been linked to an increased risk of CVD 
also in other chronic diseases, such as heart failure and cancer.30 31 In our study, the PAR for LDL-c 
among men was negative, indicating that lowering LDL-c may not reduce CVD risk among men. This 
is consistent with other reports of a modest impact of lipids on future CVD in RA. In addition, 
Schnohr et al 27 reported low PAR of 9% among men and 12% among women for 
hypercholesterolaemia, despite high hypercholesterolaemia prevalence of 47% among men and 57% 
among women. With lower prevalence rates of hypercholesterolaemia in RA than in the general 
population, it is not surprising that our PAR for lipids were low. 
 
The RA-specific variables seem to have a greater impact on CVD among women than men. While the 
prevalence of RF/ACPA positivity and DAS28 levels was similar between the sexes, the effect sizes of 
RA characteristics appeared to be larger among women than men, despite lack of statistical 
significance. Moreover, higher levels of ESR in women than men may partially explain this apparent 
difference in PAR. Furthermore, RA disease duration was longer among women, and more women 
than men were receiving biological DMARDs at baseline. 
 
Of interest, the PAR for DAS28 and for RF/ACPA positivity were comparable in magnitude to the PAR 
for TC, underscoring the importance of RA characteristics in attributing CVD outcomes among 
patients with RA. Altogether, RA characteristics accounted for 30% of the CVD risk. These findings 
indicate that RA characteristics play an important role in efforts to reduce CVD risk among patients 
with RA. 
 
Strengths of this study include its large sample size that comprised several diverse cohorts of 
patients with RA, as well as the careful assessment of RA characteristics and CVD risk factors in these 
cohorts. In addition, most of the cohorts were either population-based or included all consecutive 
patients, which should reduce selection bias issues. However, several cohorts were developed at 
referral centres, so the possibility of referral bias cannot be excluded. Limitations include the 
possibility of differences in measurement of CVD risk factors and CVD events despite agreement on 
variable definitions across cohorts. Moreover, patient counselling and aggressive treatment of CVD 
risk at some centres may limit generalisability of our findings. Finally, RA characteristics were 
measured at the single time point of study inclusion. As RA disease activity fluctuates over time, 
assessment at a single time point may lead to underestimation of the impact of RA characteristics on 
development of CVD events. 
 
In this large, international cohort of patients with RA, no significant sex differences were observed 
concerning the risk factors’ effect on future CVD. Furthermore, the importance of various CVD risk 
factors differed from what is reported from other patient populations. Knowledge regarding the 
impact of various risk factors on CVD events is essential to individualise CVD risk evaluation and 
prevention for patients with RA. Optimal management of CVD risk factors continues to be an 
important goal of CVD risk management in patients with RA as evidenced by the sizeable proportion 
of CVD risk attributable to CVD risk factors. Furthermore, the substantial proportion of CVD risk 
attributable to RA characteristics indicates that RA disease activity and severity play an important 
role in efforts to reduce CVD risk among patients with RA. 
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